Literature DB >> 3009377

Amplifications of both c-Ki-ras with a point mutation and c-myc in a primary pancreatic cancer and its metastatic tumors in lymph nodes.

H Yamada, H Sakamoto, M Taira, S Nishimura, Y Shimosato, M Terada, T Sugimura.   

Abstract

Activated c-Ki-ras with a point mutation (GGT to CGT) at codon 12, resulting in the substitution of arginine for glycine, was found in DNA from metastatic pancreatic adenocarcinoma in a lymph node. By means of restriction endonuclease length polymorphism with SacI digestion, we were able to demonstrate that the same point mutation of c-Ki-ras was present in the primary tumor and in metastases in lymph nodes. DNA from the normal spleen of the patient did not have this type of point mutation. Moreover, amplifications of 3- to 6-fold of the activated c-Ki-ras and 50-fold of c-myc were found in the primary tumor and the metastases in the two lymph nodes, indicating that point mutation had occurred at a relatively early stage of the tumor development, before amplification of the gene. This is the first clear demonstration of amplification of activated c-Ki-ras accompanied by amplification of c-myc in both primary and metastatic human tumors in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009377

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  23 in total

Review 1.  Pancreatic ductal adenocarcinoma and transcription factors: role of c-Myc.

Authors:  Anouchka Skoudy; Inmaculada Hernández-Muñoz; Pilar Navarro
Journal:  J Gastrointest Cancer       Date:  2011-06

2.  Isolation of genes specifically expressed in flat revertant cells derived from activated ras-transformed NIH 3T3 cells by treatment with azatyrosine.

Authors:  W J Krzyzosiak; N Shindo-Okada; H Teshima; K Nakajima; S Nishimura
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

Review 3.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

4.  Overexpression of c-Ki-ras and c-fos in human pancreatic carcinomas.

Authors:  K Wakita; H Ohyanagi; K Yamamoto; T Tokuhisa; Y Saitoh
Journal:  Int J Pancreatol       Date:  1992-02

Review 5.  Human cancer and cellular oncogenes.

Authors:  S Nishimura; T Sekiya
Journal:  Biochem J       Date:  1987-04-15       Impact factor: 3.857

6.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

7.  Rare codons regulate KRas oncogenesis.

Authors:  Benjamin L Lampson; Nicole L K Pershing; Joseph A Prinz; Joshua R Lacsina; William F Marzluff; Christopher V Nicchitta; David M MacAlpine; Christopher M Counter
Journal:  Curr Biol       Date:  2012-12-13       Impact factor: 10.834

8.  DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC.

Authors:  Jinfei Xu; Joseph R Testa
Journal:  J Biol Chem       Date:  2009-06-04       Impact factor: 5.157

9.  KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas.

Authors:  Alyssa M Krasinskas; A James Moser; Burcu Saka; N Volkan Adsay; Simion I Chiosea
Journal:  Mod Pathol       Date:  2013-04-19       Impact factor: 7.842

10.  A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth.

Authors:  Hiroaki Mita; Minoru Toyota; Fumio Aoki; Hirofumi Akashi; Reo Maruyama; Yasushi Sasaki; Hiromu Suzuki; Masashi Idogawa; Lisa Kashima; Kazuyoshi Yanagihara; Masahiro Fujita; Masao Hosokawa; Masanobu Kusano; Sorin Vasile Sabau; Haruyuki Tatsumi; Kohzoh Imai; Yasuhisa Shinomura; Takashi Tokino
Journal:  BMC Cancer       Date:  2009-06-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.